Autologous cancer vaccine using patients' own tumor to prevent the recurrence of colon cancer & other carcinomas. $5b revenue potential.
Prevents recurrence of cancer by using the patient's own tumor to make a patient-specific vaccine. The first customers are those with stage II colon cancer followed by stage III, renal, melanoma, ovarial and possibly lung cancer. All solid tumors are potentially treated using our patented vaccine approach. In the last phase 3 trial, recurrence dropped from 1 out of 3 patients to 1 out of 10 patients. We make colon cancer a manageable disease.